(Q37686055)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Management of breast cancer with targeted agents: importance of heterogeneity. [corrected] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

José Baselga

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

2 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

139-147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

Molecular portraits of human breast tumours

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

The phosphoinositide 3-kinase pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Status of PI3K inhibition and biomarker development in cancer therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Weekly paclitaxel in the adjuvant treatment of breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

31 March 2020

The hunting of the Src

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Cellular functions regulated by Src family kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

31 March 2020

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

The interplay between Src family kinases and receptor tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.234

Understanding and treating triple-negative breast cancer

31 March 2020

1 reference

12 December 2020

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

1 reference

12 December 2020

Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.

1 reference

12 December 2020

Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product.

1 reference

12 December 2020

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

12 December 2020

10.1038/NRCLINONC.2009.234

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20125090%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference